Volumetric parameters on 18F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET
Volumetric parameters on 18F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET
复制标题
18F-FDG PET/CT 的体积参数预测与其 c-MET 表达状态相关的胃癌患者的生存率
DOI：
10.1186/s12885-019-5935-3
复制
发表时间：
2019-08-08
期刊：
影响因子：
3.8
通讯作者：
Shi, Hongcheng
中科院分区：
文献类型：
--
作者：
Liu, Guobing;Hu, Yan;Shi, Hongcheng
背景：本研究旨在根据c-MET （MET原癌基因，受体酪氨酸激酶）的表达情况，探讨体积参数对胃癌患者预后的价值。方法：对61例晚期胃癌患者进行研究。收集基线数据：18f - fdg PET/CT、临床病理信息、无进展生存期（PFS）和总生存期（OS）。在PET/CT上测量胃原位肿瘤的最大标准化摄取值（SUVmax）、峰值SUV （SUVpeak）、代谢肿瘤体积（MTV）和病灶糖酵解总量（TLG）。免疫组织化学染色记录c-MET的表达情况。分析PET/CT参数与患者生存结局之间与c-MET表达状态的关系。结果：c-MET表达阳性患者的PFS （11.5 vs. 17.6个月，P = 0.039）和OS （17.0 vs. 24.3个月，P = 0.043）较c-MET表达阴性患者明显缩短，且胃癌肿瘤MTV（70.8±53.11 vs. 41.1±52.32,P = 0.034）和TLG（428.39±442.95 vs. 205.7±354.40,P = 0.039）较大。两组患者的SUVmax（9.6±7.40 vs 8.0±4.91,P = 0.335）和SUVpeak（7.7±5.99 vs 6.62±4.08,P = 0.438）差异无统计学意义。在c- met阳性肿瘤患者中，MTV和TLG是预测患者远处转移矫正后OS的独立因素（危险比分别为1.014和1.002；P分别为0.024和0.027），而在c- met阴性肿瘤患者中，这些相关性不显著。结论：c- met阳性胃癌患者的MTV和TLG值高于c- met阴性胃癌患者。在c- met阳性胃癌患者中，18f - fdg PET/CT上的体积参数对患者总体生存具有预后价值。
Background:This study aimed to investigate the prognostic value of volumetric parameters on18F- fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in gastric-cancer patients, according to the expression status of c-MET (MET proto-oncogene, receptor tyrosine kinase), which was previously unclear.Methods:The study included 61 patients with advanced gastric cancer. Data on the baseline18F-FDG PET/CT, clinical-pathological information, progression-free survival (PFS), and overall survival (OS) were collected. The maximum standardized uptake value (SUVmax), peak SUV (SUVpeak), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of gastric tumors in situ were measured on PET/CT. The expression status of c-MET was recorded based on immunohistochemical staining. Associations between the parameters on PET/CT and patients' survival outcomes were analyzed in relation to expression status of c-MET.Results:Patients with positive c-MET expression had significantly shorter PFS (11.5 vs. 17.6 months, P = 0.039) and OS (17.0 vs. 24.3 months, P = 0.043), and had gastric tumors with a larger MTV (70.8 ± 53.11 vs. 41.1 ± 52.32, P = 0.034) and TLG (428.39 ± 442.95 vs. 205.7 ± 354.40, P = 0.039), compared with those with negative c-MET expression. However, SUVmax(9.6 ± 7.40 vs. 8.0 ± 4.91, P = 0.335) and SUVpeak(7.7 ± 5.99 vs. 6.62 ± 4.08, P = 0.438) were similar between these two patient groups. In patients with c-MET-positive tumors, MTV and TLG were independent factors in predicting patient OS after correction by distant metastasis (hazards ratio = 1.014 and 1.002, respectively; P = 0.024 and 0.027, respectively), while these associations were not significant in patients with c-MET-negative tumors.Conclusions:Patients with c-MET-positive gastric cancer had higher MTV and TLG values compared to those with c-MET-negative gastric cancer. In patients with c-MET-positive gastric cancer, volumetric parameters on18F-FDG PET/CT have prognostic value for patient overall survival.